---
figid: PMC6480014__ijms-20-01692-g002
figlink: /pmc/articles/PMC6480014/figure/ijms-20-01692-f002/
number: Figure 2
caption: Rationale for combining immune checkpoint inhibitors with antiangiogenic
  drugs, anti-tumor immune response modulation adapted from Amin et al. Frontiers
  in Oncology. 2019. TCR, T cell receptor; MDSC, myeloid derived suppressor cells;
  VEGF, vascular endothelial growth factor; PD-1, programmed death 1; PD-L1, programmed
  death ligand 1; CTLA 4, cytotoxic T lymphocyte antigen 4.
pmcid: PMC6480014
papertitle: Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma.
reftext: Sol√®ne-Florence Kammerer-Jacquet, et al. Int J Mol Sci. 2019 Apr;20(7):1692.
pmc_ranked_result_index: '157718'
pathway_score: 0.8672989
filename: ijms-20-01692-g002.jpg
figtitle: Rationale for combining immune checkpoint inhibitors with antiangiogenic
  drugs, anti-tumor immune response modulation adapted from Amin et al
year: '2019'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6480014__ijms-20-01692-g002.html
  '@type': Dataset
  description: Rationale for combining immune checkpoint inhibitors with antiangiogenic
    drugs, anti-tumor immune response modulation adapted from Amin et al. Frontiers
    in Oncology. 2019. TCR, T cell receptor; MDSC, myeloid derived suppressor cells;
    VEGF, vascular endothelial growth factor; PD-1, programmed death 1; PD-L1, programmed
    death ligand 1; CTLA 4, cytotoxic T lymphocyte antigen 4.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CTLA4
  - IDO1
  - CD274
  - TRA
  - TRB
  - PDCD1
  - KDR
  - FLT4
  - TRD
  - FLT1
  - TRG
  - TCR
  - Sunitinib
  - Pazopanib
  - Cabozantinib
  - "\x1F Cytotoxic T"
  - Cytotoxic
genes:
- word: CTLA-4
  symbol: CTLA4
  source: hgnc_symbol
  hgnc_symbol: CTLA4
  entrez: '1493'
- word: IDO1
  symbol: IDO1
  source: hgnc_symbol
  hgnc_symbol: IDO1
  entrez: '3620'
- word: PD-L1
  symbol: PD-L1
  source: hgnc_alias_symbol
  hgnc_symbol: CD274
  entrez: '29126'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRA
  entrez: '6955'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRB
  entrez: '6957'
- word: PD-1
  symbol: PD-1
  source: hgnc_alias_symbol
  hgnc_symbol: PDCD1
  entrez: '5133'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT4
  entrez: '2324'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRD
  entrez: '6964'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT1
  entrez: '2321'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRG
  entrez: '6965'
chemicals:
- word: TCR
  source: MESH
  identifier: D017260
- word: Sunitinib
  source: MESH
  identifier: C473478
- word: Pazopanib
  source: MESH
  identifier: C516667
- word: Cabozantinib
  source: MESH
  identifier: C558660
diseases:
- word: "\x1F Cytotoxic T"
  source: MESH
  identifier: D064420
- word: Cytotoxic
  source: MESH
  identifier: D064420
---
